Alcohol-associated severe hyperhomocysteinaemia

Gillett, Melissa J; Burnett, John R.

doi:10.1258/0004563054255489

Cited by 3 publications

(3 citation statements)

References 22 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood glucose measured in fasting state or after an oral glucose tolerance test has been used to diagnose type-2 diabetes. More recently, HbA1c levels have been recommended for the diagnosis of diabetes and pre-diabetes [7]. It reflects mean levels of glucose integrated over the life span of the protein.…”

Section: Advances In Diagnosismentioning

confidence: 99%

An update on diagnosis and therapeutics for type-2 diabetes mellitus

Babu¹

2023

Bioinformation

View full text Add to dashboard Cite

Type-2 Diabetes mellitus is a common metabolic disorder and is combined with co-morbidities, such as obesity, hyperlipidemia, hypertension and cardiovascular disease which taken together, comprise the ‘Metabolic Syndrome’. This disease causes crucial morbidity and mortality at considerable expense to patients, their families and society. Different categories of drugs such as insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, GLP-1 agonists, DPP4 inhibitors, Dual PPAR agonists etc are used for its management. In this review, we have highlighted the recent advances in diagnosis and therapeutics used in the treatment of type-2 diabetes mellitus. The classical and online-literature were studied in order to compile the data which includes the electronic search engine such as Scopus, Google Scholar, Sci Finder, PubMed and Web of Science etc. The scientific data showed that at present, there are different families of oral and injectable drugs are at hand for the treatment of T2DM which has deleterious side effects. Hence, we need to develop a novel, safety and effective agents that will improve the quality of life of T2DM patients, considering the properties of the treatment such as effectiveness and durability of lowering blood Glucose, risk of hypoglycemia and diabetes complications.

show abstract

Section: Advances In Diagnosismentioning

confidence: 99%

An update on diagnosis and therapeutics for type-2 diabetes mellitus

Babu¹

2023

Bioinformation

View full text Add to dashboard Cite

show abstract

“…However, Saw et al (2001) documented that in smokers, the increase in plasma Hcy levels, disappeared after correction for plasma folate. Another one factor that could be able to induce hyper-Hcy is the high alcohol; however, also this phenomenon in reversible and resolved after the dismission of alcohol intake (de Bree et al 2002, Blasco et al 2005, Gillet and Burnett 2005. In added, Blasco et al (2005), documented that chronic alcoholics with liver damage presents higher levels of plasma Hcy levels respect to chronic alcoholics with normal liver, suggesting that the liver impairment may represent an important mechanism involved in the regulation of plasma Hcy levels.…”

Section: Lifestyle Factors and Homocysteine (Hcy)mentioning

confidence: 99%

Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa

Siniscalchi

Gallelli²,

Mercuri

et al. 2006

Nutritional Neuroscience

View full text Add to dashboard Cite

Many papers documented that Parkinson's disease (PD) patients treated with levodopa (L-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that L-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during L-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.

show abstract

“…The former defect occurs in B 6 deficiency or serine deficiency or in classical homocystinuria/cystathionine beta-synthase (CBS) deficiency 3 20 21. The latter defect maybe acquired in renal failure, hypothyroidism, alcohol or methotrexate use and inherited in CblE, CblG, MTHFR (methyltetrahydrofolate reductase) deficiency (see figure 1 for abbreviations and for place of relevant enzyme in pathway) 19 22–25…”

mentioning

confidence: 99%